INmune Bio, Inc.
General ticker "INMB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $109.5M (TTM average)
INmune Bio, Inc. does not follow the US Stock Market performance with the rate: -27.0%.
Estimated limits based on current volatility of 4.2%: low 1.51$, high 1.65$
Factors to consider:
- Total employees count: 10 as of 2022
- Top business risk factors: Significant losses, FDA clinical hold, Need for additional capital, Liquidity and credit risks, Dependence on key products
- Current price 13.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.49$, 6.66$]
- 2025-12-31 to 2026-12-31 estimated range: [1.99$, 5.28$]
Financial Metrics affecting the INMB estimates:
- Positive: with PPE of -2.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -36.60 <= 0.04
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 81.13 > 64.17
- Positive: Investing cash flow per share per price, % of 0 > -0.62
Short-term INMB quotes
Long-term INMB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.37MM | $0.15MM | $0.01MM |
| Operating Expenses | $26.32MM | $29.90MM | $42.65MM |
| Operating Income | $-25.95MM | $-29.74MM | $-42.63MM |
| Non-Operating Income | $-1.35MM | $-0.27MM | $0.55MM |
| R&D Expense | $17.07MM | $20.27MM | $33.17MM |
| Income(Loss) | $-27.30MM | $-30.01MM | $-42.08MM |
| Profit(Loss)* | $-27.30MM | $-30.01MM | $-42.08MM |
| Stockholders Equity | $60.10MM | $37.34MM | $32.10MM |
| Assets | $81.80MM | $57.00MM | $39.56MM |
| Operating Cash Flow | $-22.69MM | $-11.98MM | $-33.36MM |
| Financing Cash Flow | $0.73MM | $-4.22MM | $18.21MM |
| Earnings Per Share** | $-1.52 | $-1.67 | $-2.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.